Regenerative medicine regulatory policies: A systematic review and international comparison

Tingting Qiu, Eve Hanna, Monique Dabbous, Borisov Borislav and Mondher Toumi

Health Policy, 2020, vol. 124, issue 7, 701-713

Abstract: A small number of regenerative medicines (RMs) have received market authorization (MA) worldwide, relative to the large number of clinical trials currently being conducted. Regulatory issues constitute one major challenge for the MA of RMs.

Keywords: Regenerative medicine; Market authorization; Expedited programs (search for similar items in EconPapers)
Date: 2020
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851020301032
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:124:y:2020:i:7:p:701-713

DOI: 10.1016/j.healthpol.2020.05.004

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().